Evan David Seigerman

Evan David Seigerman is an analyst at BMO Capital Markets, recognized for his insights into the pharmaceutical industry, particularly in relation to market trends and company performance. He has recently highlighted the potential impact of Novo Nordisk's approval of Wegovy for treating metabolic dysfunction-associated steatohepatitis (Mash) on the company's market position, noting that this approval could help reverse a challenging start to the year for Novo Nordisk.